Specify Company / Ticker to Get the Summary
Compass Pathways Plc
CMPSCOMPASS Pathways plc operates as a mental health care company in the United Kingdom and the United States. It develops COMP360, a psilocybin therapy that is in Phase III clinical trials for the treatment of treatment-resistant depression; and is in Phase II clinical trials for the treatment of post-traumatic stress disorder and anorexia nervosa. The company was formerly known as COMPASS Rx Limited and changed its name to COMPASS Pathways plc in August 2020. COMPASS Pathways plc was incorporated in 2020 and is headquartered in London, the United Kingdom. Address: 33 Broadwick Street, London, United Kingdom, W1F 0DQ
Analytics
WallStreet Target Price
21.22 USDP/E ratio
–Dividend Yield
–Current Year
Last Year
Current Quarter
Last Quarter
Current Year
Last Year
Current Quarter
Last Quarter
Key Figures CMPS
Dividend Analytics CMPS
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CMPS
Stock Valuation CMPS
Financials CMPS
Results | 2019 | Dynamics |